Therapeutics

Breaking News

1 Apr 2015 The BACE inhibitor JNJ-5486911 reduced Aβ 37, 38, 40, and 42 in the cerebrospinal fluid of healthy volunteers. The drug's first phase 1 results reflect extensive CSF monitoring. See news

31 Mar 2015 The first clinical trial data for PRX002, a monoclonal antibody against aggregated α-synuclein, suggest that it reduced free α-synuclein in the serum of healthy volunteers. A second trial in Parkinson’s patients is ongoing. See news.

This database provides a catalog of the therapeutics currently or previously tested as treatment for Alzheimer's disease and related disorders, focusing on those that have progressed to Phase 2 or beyond in U.S. clinical trials. We strive to keep this database up-to-date and welcome you to contact us at therapeutics@alzforum.org.

Tools

Back to the Top
Search Therapeutics

AD Target / Therapy Types

The two tables below organize the therapeutics within this database by therapy type and proposed target type. The number of therapeutics within each category is indicated according to the highest phase each therapeutic has achieved in U.S. clinical trials. For example, if a given therapeutic is in both Phase 2 and Phase 3 trials, it is included in the Phase 3 total.

Further Reading

News

  1. At AD/PD Conference, New BACE Inhibitor Struts Its Stuff
  2. Antibody Against α-Synuclein Looks Safe In Early Trials
  3. Biogen Antibody Buoyed by Phase 1 Data and Hungry Investors
  4. More Evidence That Epilepsy Drug Calms Neurons and Boosts Memory

Webinars

  1. Resolving Controversies on the Path to AD Therapeutics
  2. Treating Before Symptoms—ADCS Invites Ideas for Clinical Trials in Very Early AD
  3. Of Mice and Men: Bridging the Translational Disconnect in CNS Drug Discovery
  4. Can We (Should We?) Develop “Smart Drugs” to Stave Off Age-Related Memory Loss?

Other Resources

ADDF ACCESS is a program to provide scientists in academia and small biotechnology companies with access to a virtual network of drug discovery experts and contract research organizations (CROs) that have experience developing therapies for neurodegenerative diseases.

Patient Resources